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AbsTrACT
background Uveitis is inflammation inside the eye. The 
objective of this study is to assess the cost-effectiveness 
of a dexamethasone implant plus current practice 
(immunosuppressants and systemic corticosteroids) 
compared with current practice alone, in patients with 
non-infectious intermediate, posterior or pan-uveitis and 
to identify areas for future research.
Methods A Markov model was built to estimate the costs 
and benefits of dexamethasone. Systematic reviews were 
performed to identify available relevant evidence. Quality of 
life data from the key randomised-controlled trial (HURON) 
was used to estimate the interventions’ effectiveness 
compared with the trial’s comparator arm (placebo plus 
limited current practice (LCP)). The analysis took a National 
Health Service and Personal Social Services perspective. 
Costs were calculated based on standard UK sources.
results The incremental cost-effectiveness ratio (ICER) 
of one dexamethasone implant compared with LCP 
is estimated as £19 509 per quality-adjusted life year 
(QALY) gained. The factors with the largest impact on 
the results were rate of blindness and relative proportion 
of blindness cases avoided by dexamethasone. Using 
plausible alternative assumptions, dexamethasone could 
be cost saving or it may be associated with an ICER of 
£56 329 per QALY gained compared with LCP.
Conclusions Dexamethasone is estimated to be cost-
effective using generally accepted UK thresholds. However, 
there is substantial uncertainty around these results due 
to scarcity of evidence. Future research on the following 
would help provide more reliable estimates: effectiveness 
of dexamethasone versus current practice (instead of LCP), 
with subgroup analyses for unilateral and bilateral uveitis, 
incidence of long-term blindness and effectiveness of 
dexamethasone in avoiding blindness.
InTroduCTIon
Uveitis is a group of conditions characterised by 
inflammation inside the eye. Complications of 
uveitis including cystoid macular oedema, vitreous 
haze, cataracts, glaucoma and irreversible damage to 
the retina may lead to loss of vision. Uveitis gener-
ally presents in people of working age and accounts 
for 10% of cases of legal blindness, defined here as 
best-corrected visual acuity of 20/200 or less in the 
better-seeing eye and/or a visual field of 20 degrees 
or less.1
Dexamethasone intravitreal implant (Ozurdex, 
Allergan) is a corticosteroid implant which 
suppresses inflammation by inhibiting the 
expression of proinflammatory mediators. Dexa-
methasone implant has a marketing authorisation 
from the European Medicines Agency for treating 
adults with inflammation of the posterior segment 
of the eye presenting as non-infectious uveitis.2 The 
prevalence of non-infectious posterior segment-in-
volving uveitis is estimated to be between 3 and 10 
out of 100 000 people.2
Non-infectious posterior segment-involving 
uveitis is usually treated with corticosteroids first 
line, which may be administered systemically or 
locally. Long-term use of systemic corticosteroids 
above 7.5 mg per day is not recommended due to 
the side effects which include cataract, glaucoma, 
diabetes, osteoporosis, weight gain and raised 
blood pressure. Second-line treatment is typically 
immunosuppressive drugs including methotrexate, 
mycophenolate mofetil, cyclosporin, tacrolimus 
and azathioprine, and these can allow a reduction 
in the corticosteroid dose and associated compli-
cations. It is expected that dexamethasone implant 
could provide an alternative second-line option for 
patients who have unilateral uveitis or asymmetric 
bilateral uveitis, where systemic disease is not 
present or is well controlled.
However, national funding bodies need to know 
if dexamethasone implants are cost-effective in 
order to inform recommendations for clinical prac-
tice. To our knowledge, this is the first economic 
evaluation of the dexamethasone implant in 
patients with non-infectious uveitis. The objective 
of this study is to assess the cost-effectiveness of 
dexamethasone compared with current practice in 
England in patients with non-infectious interme-
diate, posterior or panuveitis and to identify areas 
for future research.
MeThods
A systematic review of existing economic eval-
uations was undertaken of the dexamethasone 
implant for non-infectious uveitis. Since no rele-
vant economic evaluations were identified from the 
review, a de novo economic model was developed. 
Systematic reviews were also undertaken of the 
effectiveness evidence and utility estimates, which 
have been described elsewhere.3
health economic model scope
The model population consists of adults with active 
non-infectious intermediate, posterior or pan 
uveitis, with a mixture of unilateral and bilateral 
uveitis.
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Figure 1 State transition diagram of the decision model.
The comparator is current UK practice, which for the main 
analysis is assumed to be equivalent to the control arm of the 
main randomised controlled trial of the dexamethasone implant, 
HURON.4 In this group, 25% of patients were using systemic 
immunosuppressants (such as methotrexate, mycophenolate 
mofetil, cyclosporine and azathioprine) or anti-inflammatory 
treatment at baseline and they were allowed rescue therapy 
with new corticosteroids or immunosuppressants. In current UK 
practice, a greater proportion of patients are likely to receive 
the systemic immunosuppressants or anti-inflammatory treat-
ment than in the control arm of the HURON trial. As such 
the comparator for the main analysis is denoted throughout 
as limited current practice based on HURON (limited current 
practice (LCP)(H)). An exploratory analysis was also undertaken 
to assess the impact of alternative baseline effectiveness, based 
on the comparator of the Multicentre Uveitis Steroid Treat-
ment (MUST) trial.5 A systematic review was undertaken which 
found no other evidence of the effectiveness of the dexametha-
sone implant from a randomised controlled trial. Observational 
studies of the implant have been reported and these are discussed 
later; however, they do not provide evidence of the relative 
impact of dexamethasone. The intervention being assessed is 
one 0.7 mg dexamethasone implant provided in one eye, plus 
LCP(H), to be consistent with the HURON trial.4
The main outcome of the model is the incremental cost 
per quality-adjusted life year (QALY) gained for dexametha-
sone compared with current practice. QALYs are estimated by 
assigning a health-related utility value to each health state in the 
model, where zero is equivalent to death and one is equivalent 
to full health, and summing these over the patients’ lifetime. 
The incremental cost per QALY gained is the difference in costs 
associated with the dexamethasone implant and current practice 
divided by the difference in QALYs associated with the dexa-
methasone implant and current practice. This outcome allows 
the cost-effectiveness of dexamethasone to be compared against 
other healthcare interventions for different populations and 
indications. The analysis is performed from a National Health 
Service (NHS) and Personal Social Services (PSS) perspective 
and costs and QALYs are discounted at a rate of 3.5% per year 
as recommended by the National Institute for Health and Care 
Excellence (NICE),6 since this work was used to inform a deci-
sion about how to spend NHS and PSS resources.7 An accom-
panying model of adalimumab for this population was also 
developed to inform the same NICE guidance, which is reported 
elsewhere.8 9
health economic model design
A Markov model was developed, which simulates a cohort of 
patients through a set of mutually exclusive health states, with 
probabilities of moving between the states every time cycle. 
Patients enter the model with a mean age of 44.8, based on 
HURON,4 and are followed over a lifetime.
There are four health states: (1) dexamethasone implant, 
no blindness; (2) no dexamethasone implant, no blindness; 
(3) blindness and (4) death, as shown in figure 1. Patients in 
the dexamethasone implant group start in the ‘dexamethasone 
implant, no blindness’ state and move to the ‘no dexamethasone 
implant effect, no blindness’ state after 30 weeks. Patients in the 
comparator group begin immediately in the ‘no dexamethasone 
implant effect, no blindness’ state. Each 2-weekly cycle, patients 
have a probability of experiencing permanent damage to the 
eye, transitioning to ‘blindness’. Patients can also transition to 
the ‘death’ state. Treatment benefit is represented with higher 
health-related quality of life (HRQoL) and lower rates of condi-
tion-related adverse events (AEs) while in the ‘dexamethasone 
implant, no blindness’ state, as well as a reduced risk of perma-
nent blindness. The health states of the model were chosen to 
reflect the events which were thought to have the largest impact 
on costs and quality of life. Searches were undertaken around 
the disease natural history of blindness for uveitis patients to 
inform the transitions between health states.
Model inputs
Model inputs were taken from a variety of sources. A summary 
of these parameters are included in table 1.
health-related quality of life
The Visual Function Questionnaire-25 (VFQ-25) health-related 
quality of life (HRQoL) outcome was used because it captured 
most fully the positive and negative effects of the implant. The 
use of visual acuity and vitreous haze outcomes within the model 
were also considered; however, the VFQ-25 was preferred 
because of the difficulties associated with capturing all impacts 
of the dexamethasone implant using one visual outcome. The 
HURON trial4 reports VFQ-25 HRQoL data at baseline and at 
each follow-up visit.
Another HRQoL measure that was collected at baseline within 
the trial was the five dimensional EuroQol (EQ-5D) measure, 
including mobility, self-care, usual activities, pain/discomfort and 
anxiety/depression. This is a standardised instrument which is 
considered to be the gold standard in order to compare HRQoL 
across a wide range of health conditions and treatments. It is 
necessary to convert VFQ-25 data to EQ-5D utilities in order 
to estimate QALYs, as required by NICE in order to enable a 
comparison of the cost-effectiveness of all interventions across 
different patient populations. The manufacturer of the dexa-
methasone implant, Allergan, shared patient-level data from the 
HURON trial with the project team which allowed an analysis of 
the relationship between VFQ-25 and EQ-5D using the baseline 
data.
A linear regression model was fitted to the data from HURON 
to predict EQ-5D utilities from the VFQ-25, as shown in figure 2, 
assuming that the relationship is independent of treatment.
EQ-5D utility=0.4454059 + VFQ-25 score*0.0051322
Alternative non-linear models (eg, quadratic regression) were 
also tested but did not significantly improve the fit to the data.
The utility for patients entering the model was set to be 
the same for both the dexamethasone implant group and the 
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Table 1 Model input parameters for the base case analysis
Parameters Mean distribution used in PsA source
  Starting age (active/inactive) 44.8 Fixed HURON4
  Discount rate (costs and utilities) 3.5% Fixed NICE reference case6
  Gender (% males) 36.7% Fixed HURON4
  Cycle length 2 weeks Fixed
Utilities 
  Baseline VFQ-25 for the dexamethasone implant and LCP(H) 66.63 Beta HURON4
  Blindness utility 0.38 Multivariate normal Czoski-Murray et al13
  Proportion of patients with uveitis with bilateral disease in the UK 75% Beta Expert clinical opinion
  Proportion of patients with uveitis with bilateral disease in the HURON trial 70% Beta Combination of patient level data from the 
HURON trial4 and clinical opinion
  Probability of blindness (annual) 0.0068 Beta Dick et al10
  Relative risk of blindness for dexamethasone versus no implant during 6-month 
period following implantation
0.5 Uniform Assumption
Drug costs 
  Dexamethasone 0.7 mg £870 Fixed BNF, 201618
  Prednisolone £1.24 Fixed BNF19
  Mycophenolate mofetil £9.31 Fixed BNF19
  Methotrexate £2.40 Fixed BNF19
  Cyclosporin £48.50 Fixed BNF19
  Azathioprine £3.24 Fixed BNF19
  Bimatoprost £11.71 Fixed BNF19
  Adcal D3 £7.49 Fixed BNF19
  Omeprazole £1.17 Fixed BNF19
Administration and monitoring
  Monitoring visit frequency 6 weeks Jabs et al20
  Monitoring visit cost £96.11 Gamma NHS reference costs 2014–201521
  Dexamethasone implant administration cost £113.42 Gamma NHS reference costs 2014–2015, minor 
vitreous retinal procedures21
Costs of adverse events 
  Cataract surgery £852.40 Gamma NHS reference costs 2014–1521
  Raised intraocular pressure £23.42 Gamma BNF19
  Glaucoma procedure £581.25 Gamma NHS reference costs 2014–201521
  Hypertension £7.04 Gamma Breeze et al22
  Blindness (transition) £237 Gamma Colquitt et al23
  Blindness (annual) £7659 Gamma Colquitt et al23
  Fracture £2,116.17–
£6022.62
Gamma Davis et al24
  Diabetes £1521.46 Gamma Alva et al,25 Breeze et al22
BNF, British National Formulary; LCP, limited current practice; NHS, National Health Service; NICE, National Institute for Health and Care Excellence; PSA, probabilistic sensitivity 
analyses; VFQ, Visual Function Questionnaire.
Figure 2 The relationship between Visual Function Questionnaire-25 
(VFQ-25) and EuroQol- 5 Dimension (EQ-5D) based on patient-level data 
from the HURON trial.
comparator by calculating the average VFQ-25 from these two 
arms of the HURON trial and using the linear regression to 
predict the EQ-5D utility. Utility over time was estimated using 
the VFQ-25 data from the HURON trial at 8, 16 and 26 weeks, 
adjusted by the baseline VFQ-25, to predict EQ-5D at these time 
points using the linear regression.
Permanent blindness
A goal of the use of the dexamethasone implant is to prevent 
permanent damage to the eye. It was therefore important to 
include a rate of blindness and the impact of dexamethasone 
on that rate. However, this outcome was not captured by the 
HURON trial due to its short duration.4 Given the lack of 
evidence, only blindness in both eyes was incorporated into the 
model. A study by Dick et al10 was used to estimate the rate 
of blindness for people with uveitis receiving current care. This 
was a retrospective analysis of insurance claims data (n=1769) 
where all patients had posterior segment, non-infectious uveitis 
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Table 2 Model results
Total QALYs Total costs Inc. QALYs Inc. costs ICer
Probability of cost-effectiveness at 
WTP threshold
£20 000 £30 000
Main results (probabilistic)
  LCP(H)* 14.599 £39 992 0.53 0.28
  DEX+LCP(H)* 14.629 £40 565 0.029 £573 £19 509 0.47 0.72
Main results (deterministic)
  LCP(H)* 14.613 £39 655 N/A N/A
  DEX+LCP(H)* 14.641 £40 235 0.029 £580 £20 058 N/A N/A
Exploratory analysis 1: comparing dexamethasone with arm from the MUST trial (probabilistic)
  CP(M)† 15.152 £63 465 0.54 0.45
  DEX+LCP(H)* 
before CP(M)†
15.163 £63 681 0.011 £216 £19 899 0.47 0.55
Exploratory analysis 2: varying duration of treatment effect (deterministic)
  LCP(H) 14.613 £39 655 N/A N/A
  Dex: 26 weeks 14.637 £40 256 0.024 £600 £24 715 N/A N/A
  Dex: 30 weeks* 14.641 £40 235 0.029 £580 £20 058 N/A N/A
  Dex: 34 weeks 14.646 £40 214 0.033 £559 £16 692 N/A N/A
  Dex: 42 weeks 14.655 £40 173 0.043 £518 £12 154 N/A N/A
*LCP(H)=LCP, as provided in the HURON trial: 25% of patients on anti-inflammatory or immunosuppressant medication.
†CP(M)=CP as provided in the MUST trial: all patients on systemic steroids and 86% on systemic immunosuppressants.
CP, current practice; DEX, dexamethasone; ICER, incremental cost-effectiveness ratio; LCP, limited current practice; MUST, Multicentre Uveitis Steroid Treatment; N/A, Not 
Applicable; QALY, quality-adjusted life year; WTP, willingness to pay.
and provided an estimate of 6.6% of patients going blind within 
10 years. Two other sources were also identified and were used 
in sensitivity analyses; Tomkins-Netzer et al,11 which included a 
wider population than our target population (including patients 
with infectious and anterior uveitis) and Durrani et al12 based on 
a tertiary referral centre. It was assumed that the dexamethasone 
implant could halve the number of cases of blindness over the 6 
months that it is effective. Since there is no evidence about this 
parameter, it was varied within sensitivity analyses.
The utility associated with the ‘blindness’ health state was 
taken from a study by Czoski-Murray et al13 who used contact 
lenses to simulate blindness associated with age-related macular 
degeneration.
Adverse events
Given that quality of life data were used directly to model treat-
ment effectiveness, it was assumed that the impact on quality of 
life associated with AEs while on treatment would be already 
captured. Therefore, only the additional costs associated with 
the management of AEs were modelled and the AEs included 
within the model were limited to those where the cost of treat-
ment is substantial: cataract, raised intraocular pressure, glau-
coma, serious infections; hypertension; fractures and diabetes. 
The probabilities for AEs per cycle were calculated based on the 
incidence and mean follow-up in the HURON trial.
Costs
The model includes treatment costs, administration costs and 
monitoring costs, as well as AE costs and the cost of perma-
nent blindness, as shown in table 1. The model assumes that all 
patients would receive monitoring every 6 weeks, irrespective of 
treatment, consisting of outpatient visits to assess the efficacy of 
the treatments and to monitor the risk of AEs. It is assumed that 
patients receiving immunosuppressants would have six addi-
tional blood monitoring visits annually.
Model analysis
Probabilistic sensitivity analyses were run using Monte Carlo 
simulation with 5000 samples. This allows for non-linearity in 
the model and incorporates distributions around each model 
input parameter to capture the uncertainty around their true 
value, leading to an estimate of the uncertainty in the model 
results. Deterministic results have also been produced which 
simply use the best estimate for each parameter in the model. 
Due to the scarcity of appropriate evidence on key model param-
eters, a range of exploratory analyses were undertaken in order 
to assess the impact of alternative assumptions on the model 
results. Where deterministic and probabilistic central results are 
similar, the deterministic model can be used within exploratory 
analyses to reduce model run time.
For more details on the model, please refer to the corre-
sponding health technology assessment report.3
resuLTs
The key model results are presented in tables 2 and 3. A single 
dexamethasone implant combined with limited current practice 
as provided in the HURON trial (DEX+LCP(H)) was estimated 
to result in a probabilistic incremental cost-effectiveness ratio 
(ICER) of £19 509 per QALY gained compared with LCP (H). 
However, there is substantial uncertainty around this result. 
Based on the uncertainty around the model parameters, there is 
an estimated 72% chance that the dexamethasone implant will 
be a good use of resources if the decision-maker is willing to pay 
£30 000 for each QALY gained.
Given the paucity of evidence, a number of alternative 
assumptions have been tested within exploratory analyses to 
assess their impact on the model results. The first exploratory 
analysis considers a comparator which is more representative 
of current UK practice than the comparator arm of HURON. 
The comparator arm of the MUST trial5 (identified within 
the systematic review) is made up of patients who received 
systemic corticosteroids, supplemented in 86% of the cases with 
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Table 3 Incremental cost-effectiveness ratio when varying rate of blindness and relative risk of blindness on dexamethasone
source
rate of blindness 
(annual)
relative risk of blindness while on dexamethasone
0 (no blindness) 0.25 0.50* 0.75 1 (no effect)
Assumption 0 £48 937 £48 937 £48 937 £48 937 £48 937
Tomkins-Netzer et al11 0.0038 £17 100 £21 816 £28 089 £36 844 £49 915
Dick et al10 * 0.0066 £8688 £13 314 £20 058* £30 805 £50 627
Durrani et al12 0.0374 Dominates Dominates £557 £10 900 £56 329
‘Dominates’ means that the dexamethasone is estimated to be more effective and less costly than current care.
*Main result.
immunosuppressants and is thought to be reasonably representa-
tive of UK clinical practice. Data from this trial was used for: (1) 
an estimate of the total proportion of patients receiving cortico-
steroids and immunosuppressants in order to estimate costs; (2) 
an estimate of the HRQoL of patients and (3) the rates for any 
AEs associated with substantial resource use. It is assumed within 
this exploratory analysis that patients treated with dexametha-
sone are also able to receive immunosuppressants and cortico-
steroids. This analysis results in both arms being associated with 
greater costs and greater QALYs, while the incremental ICER 
remains similar (see table 2).
While the observational studies undertaken to date suggest 
that the treatment effect of dexamethasone is around 6 months, 
there is some uncertainty around this, with some studies 
suggesting time to treatment failure may be longer. As such, the 
second exploratory analysis varies the length of the treatment 
effect of the dexamethasone implant (see table 2) from 26 weeks 
to 42 weeks. The ICER for DEX+LCP(H) versus LCP(H) varies 
from £12 154 to £24 715 per QALY gained.
The third exploratory analysis varies the rate of blindness for 
patients receiving current care at the same time as varying the 
relative risk of blindness when receiving dexamethasone. Table 3 
shows the resulting incremental cost per QALYs gained. These 
results show that the impact of dexamethasone on blindness is a 
key model parameter and as such model results can range from 
dexamethasone being cost saving to having a cost per QALY 
above the currently accepted thresholds for cost-effectiveness 
within England. For example, if the current rate of blindness is 
taken from the study by Durrani et al12 and dexamethasone has 
no effect on the rate of permanent blindness then the dexameth-
asone implant is estimated to have a cost per QALY gained of 
£56 329 compared with current practice. Longer term research 
is needed to reduce the uncertainty around this parameter and 
hence around the model results.
The HURON trial did not provide outcomes separately for 
patients with bilateral and unilateral disease; however, these 
exploratory results suggest that the dexamethasone implant may 
not be considered to be cost-effective, using standard thresh-
olds of cost-effectiveness in England, in patients with unilat-
eral disease since it will not prevent blindness in these patients. 
However, patients may later go on to develop uveitis in the 
second eye, and hence by preserving vision in the first eye the 
implant may prevent future blindness, thus improving cost-effec-
tiveness in this group.
In addition to the above analysis, each of the key model 
parameters was modified individually within plausible ranges to 
test their impact on the model results. The only other parameter 
which impacted the ICER by more than £2000 was the utility 
associated with blindness. This utility was changed from 0.38 
(Czoski-Murray et al13) to 0.57 (Brown et al14) which resulted 
in a deterministic ICER of £25 257 per QALY gained for dexa-
methasone plus LCP(H) compared with LCP(H).
dIsCussIon
The HURON study presented outcomes at 26 weeks and no 
patients went blind within the trial period, making the model 
predictions about the proportion of patients going blind over 
the long term highly uncertain. Research around how short-
term improvements in visual acuity or inflammation relate to 
long-term effects on moderate to severe vision loss and blindness 
would provide more robust estimates of the cost-effectiveness of 
dexamethasone.
The model assumes that only one dexamethasone implant 
would be provided to patients. There are several non-ran-
domised studies with 12–24 months follow-up, which allow 
repeat implants.15–17 These studies suggest that after around 
6 months, patients’ outcomes return to those at baseline and 
second and third implants are associated with effects similar 
to first implants. Each additional implant is associated with a 
higher incidence of AEs such as intraocular pressure (IOP) and 
cataract15–17 and this would limit repeated use. The univariate 
sensitivity analyses suggested that the model is not sensitive to 
the cost of IOP or cataract, and hence, given that the cost of each 
implant is the same, the cost-effectiveness of up to three consec-
utive implants is expected to be similar to the cost-effectiveness 
of one implant. The ICER would be expected to decrease if there 
was also a cumulative impact on the reduction in blindness or if 
patients were to achieve remission after consecutive implants.
There is insufficient evidence to assess the cost-effectiveness 
of using dexamethasone implants in both eyes for a patient with 
bilateral disease. However, because the costs would essentially 
be doubled (with the exception of some monitoring costs) and 
the increment in HRQoL is likely to be lower for the second eye, 
it is expected to be less cost-effective than treatment in one eye.
This analysis takes a NHS and PSS perspective as required 
by NICE and does not include broader societal impacts such as 
productivity loss. NICE produced guidance,7 informed by this 
analysis, that dexamethasone is recommended in the NHS as an 
option for treating non-infectious uveitis in the posterior segment 
of the eye in adults with active disease and worsening vision with 
a risk of blindness. However, considerable uncertainty remains 
due to lack of evidence on the long-term treatment effect (such 
as avoiding permanent blindness and visual impairment), on 
the prevalence of permanent blindness and visual impairment 
in the target population and on utility values after the onset of 
blindness. There is a serious unmet need to gather more primary 
data in this area to support health economic decisions in uveitis 
without which inappropriate resource allocation decisions are 
more likely to be made.
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